Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia

Phase 2

Completed

Conditions: Pulmonary Disease

Interventions: Drug: Nitric Oxide
Device: respiratory support

First Posted Date: 2012-01-04

Last Posted Date: 2013-01-28

Lead Sponsor: Fudan University

Target Recruit Count: 400

Registration Number: NCT01503801

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China

Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer

Phase 1

Conditions: Rectal Cancer

Interventions: Drug: Irinotecan
Drug: Capecitabine
Radiation: Radiotherapy

First Posted Date: 2011-11-18

Last Posted Date: 2011-11-18

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT01474187

Locations: 🇨🇳
Cancer Hospital, Fudan University, Shanghai, Shanghai, China

Use of an Oxidized Regenerated Cellulose After Hepatic Surgery

Phase 2

Conditions: Liver Neoplasms

Interventions: Device: Surgicel® absorbable Haemostat

First Posted Date: 2011-09-20

Last Posted Date: 2011-09-20

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT01436721

Locations: 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China

SOX as Salvage Treatment in Nasopharyngeal Carcinoma

Phase 2

Terminated

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: S-1 plus oxaliplatin

First Posted Date: 2011-07-27

Last Posted Date: 2014-08-20

Lead Sponsor: Fudan University

Target Recruit Count: 16

Registration Number: NCT01403259

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study of Arimidex and Radiotherapy Sequencing

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Pre-radiotherapy commencement of Arimidex
Drug: Post radiotherapy commencement of Arimidex
Radiation: Radiotherapy

First Posted Date: 2011-07-26

Last Posted Date: 2014-06-25

Lead Sponsor: Fudan University

Target Recruit Count: 220

Registration Number: NCT01402193

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: radiation therapy
Biological: Nimotuzumab
Drug: chemotherapy

First Posted Date: 2011-07-26

Last Posted Date: 2011-07-26

Lead Sponsor: Fudan University

Target Recruit Count: 128

Registration Number: NCT01402180

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0

Phase 3

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: Elective nodal irradiation (ENI)
Other: Adjuvant chemotherapy only

First Posted Date: 2011-07-20

Last Posted Date: 2011-07-20

Lead Sponsor: Fudan University

Target Recruit Count: 874

Registration Number: NCT01398449

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients

Phase 2

Conditions: Breast Cancer

Interventions: Radiation: IMRT with an simultaneous integrated boost

First Posted Date: 2011-07-14

Last Posted Date: 2013-03-27

Lead Sponsor: Fudan University

Target Recruit Count: 190

Registration Number: NCT01394575

Locations: 🇨🇳
The Department of Radiation Oncology,Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: enlarge irradiation volume
Radiation: Small volume radiation
Drug: cisplatin
Drug: fluorouracil

First Posted Date: 2011-07-12

Last Posted Date: 2011-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT01391572

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: capecitabine and pseudomonas aeruginosa combination

First Posted Date: 2011-06-27

Last Posted Date: 2013-07-26

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT01380808

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy